GeneDx (NASDAQ:WGS – Get Free Report) and PACS Group (NYSE:PACS – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Institutional & Insider Ownership
61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by company insiders. Comparatively, 70.1% of PACS Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares GeneDx and PACS Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeneDx | $427.54 million | 3.29 | -$21.02 million | ($2.68) | -17.65 |
| PACS Group | $5.29 billion | 1.13 | $191.54 million | $1.56 | 24.22 |
PACS Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
GeneDx has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, PACS Group has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for GeneDx and PACS Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeneDx | 1 | 1 | 6 | 0 | 2.63 |
| PACS Group | 0 | 2 | 5 | 0 | 2.71 |
GeneDx currently has a consensus target price of $96.43, indicating a potential upside of 103.82%. PACS Group has a consensus target price of $48.00, indicating a potential upside of 27.06%. Given GeneDx’s higher probable upside, research analysts plainly believe GeneDx is more favorable than PACS Group.
Profitability
This table compares GeneDx and PACS Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeneDx | -17.58% | 9.15% | 5.21% |
| PACS Group | 4.49% | 26.47% | 4.36% |
Summary
PACS Group beats GeneDx on 8 of the 14 factors compared between the two stocks.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
About PACS Group
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
